BHC Q1 2026 Earnings Call Summary

Bausch Health (BHC) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $2.524 billion, up 12% year-over-year (YoY), with a 7% increase on an organic basis.
Adjusted EBITDA: $837 million, a 27% increase YoY.
Adjusted Gross Margin: 70.9%, up 100 basis points YoY.
Adjusted Operating Cash Flow: $374 million.
Bausch Health (excluding Bausch & Lomb):
- Revenue: $1.280 billion, up 14% YoY (9% organic).
- Adjusted EBITDA: $673 million, up 17% YoY.
- Cash flow: $319 million, nearly $200 million higher than Q1 2025.
Net Debt Reduction: Over $100 million in the first quarter.

2. Strategic Updates and Business Highlights

Performance Drivers: Strong results driven by Salix (notably Xifaxan) and Solta, with Salix revenue up 18% and Solta up 51% YoY.
R&D Initiatives: Advancements in the Phase III program for larsucosterol targeting alcohol-associated hepatitis, with a focus on a more homogeneous patient population.
Business Development: Ongoing evaluation of opportunities in therapeutic areas where Bausch has expertise, including GI, hepatology, and aesthetics.
AI Integration: Enhanced sales productivity through AI-driven insights, contributing to a 20% increase in sales productivity for Xifaxan.

3. Forward Guidance and Outlook

2026 Guidance:
- Revenue expected between $5.250 billion and $5.400 billion.
- Adjusted EBITDA forecasted between $2.875 billion and $2.950 billion.
- Adjusted operating cash flow projected between $1.200 billion and $1.275 billion.
Market Dynamics: Anticipated impacts from new tariffs on pharma products effective September 2026 included in guidance.

4. Bad News, Challenges, or Points of Concern

Market Pressures: Potential headwinds from the exit from Medicaid and 340B programs may affect growth in the latter half of the year.
Generic Competition: Planning for the entry of generic Xifaxan in January 2028, with ongoing litigation and regulatory uncertainties surrounding exclusivity.
Diversified Segment Decline: Revenue in the diversified segment decreased by 10% YoY, primarily due to lower volumes in neuroscience.

5. Notable Q&A Insights

Xifaxan Inventory Destocking: Management expects minimal destocking ahead of pricing adjustments in 2027.
Solta's Success in China: Strong performance attributed to the integration of Shibo and high demand, with expectations for continued growth.
Business Development Flexibility: While open to acquisitions, management is cautious about raising equity given current market conditions.
Larsucosterol Trial Adjustments: Changes made to the Phase III trial design to ensure a more effective patient selection process and increase the probability of success.

Overall, Bausch Health reported a strong start to 2026, driven by solid operational execution and strategic initiatives, while also navigating potential challenges related to market dynamics and competitive pressures.

BHC — Bausch Health Companies Inc.